Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 65 references it cites were found in a registry or an index.

Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage

Open access
Le Rouzic, Erwann, Bonnard, Damien, Chasset, Sophie, Bruneau, Jean-Michel, Chevreuil, Francis, Le Strat, Frédéric, Nguyen, Juliette, Beauvoir, Roxane, Amadori, Céline, Brias, Julie, Vomscheid, Sophie, Eiler, Sylvia, Lévy, Nicolas, Delelis, Olivier, Deprez, Eric, Saïb, Ali, Zamborlini, Alessia, Emiliani, Stéphane, Ruff, Marc, Ledoussal, Benoit, Moreau, François, Benarous, Richard · 2013 · Retrovirology

Abstract

Background: LEDGF/p75 (LEDGF) is the main cellular cofactor of HIV-1 integrase (IN). It acts as a tethering factor for IN, and targets the integration of HIV in actively transcribed gene regions of chromatin. A recently developed class of IN allosteric inhibitors can inhibit the LEDGF-IN interaction. Results: We describe a new series of IN-LEDGF allosteric inhibitors, the most active of which is Mut101. We determined the crystal structure of Mut101 in complex with IN and showed that the compound binds to the LEDGF-binding pocket, promoting conformational changes of IN which explain at the atomic level the allosteric effect of the IN/LEDGF interaction inhibitor on IN functions. In vitro, Mut101 inhibited both IN-LEDGF interaction and IN strand transfer activity while enhancing IN-IN interaction. Time of addition experiments indicated that Mut101 behaved as an integration inhibitor. Mut101 was fully active on HIV-1 mutants resistant to INSTIs and other classes of anti-HIV drugs, indicative that this compound has a new mode of action. However, we found that Mut101 also displayed a more potent antiretroviral activity at a post-integration step. Infectivity of viral particles produced in presence of Mut101 was severely decreased. This latter effect also required the binding of the compound to the LEDGF-binding pocket. Conclusion: Mut101 has dual anti-HIV-1 activity, at integration and post-integration steps of the viral replication cycle, by binding to a unique target on IN (the LEDGF-binding pocket). The post-integration block of HIV-1 replication in virus-producer cells is the mechanism by which Mut101 is most active as an antiretroviral. To explain this difference between Mut101 antiretroviral activity at integration and post-integration stages, we propose the following model: LEDGF is a nuclear, chromatin-bound protein that is absent in the cytoplasm. Therefore, LEDGF can outcompete compound binding to IN in the nucleus of target cells lowering its antiretroviral activity at integration, but not in the cytoplasm where post-integration production of infectious viral particles takes place.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1742-4690-10-144

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Inhibition of IN-LEDGF interaction, correlation with ARV activity and LEDGF competition for IN binding. (A) IN-CCD/LEDGF-IBD interaction inhibition dose–response curves of the compounds listed in Table 1. Data represent the means of six independent experiments with standard deviations shown as error bars. (B) Log-log correlation plot between IC50 of CCD-IBD interaction inhibition and EC50 of ARV activity for MT4 cells infected by HxB2 HIV-1. A subset of 51 Mut101 series compounds was studied (R2 = 0.77). (C) IN-LEDGF/p75 interaction inhibition dose–response curves. Data represent the means of three independent experiments with standard deviations shown as error bars. (D) Log-log correlation plot between IC50 of IN-LEDGF/p75 interaction inhibition and EC50 of ARV activity as in (B) (R2 = 0.88). (E) IN-LEDGF/p75 interaction inhibition dose–response curves for Mut101 at various LEDGF/p75 competing concentrations ranging from 7.5 nM to 480 nM. Data represent the means of two independent experiments done in quadruplicate with standard deviations shown as error bars. (F) Correlation plot between LEDGF/p75 concentration and IC50 of Mut101 IN-LEDGF interaction (R2 = 0.94).
Figure 1 Inhibition of IN-LEDGF interaction, correlation with ARV activity and LEDGF competition for IN binding. (A) IN-CCD/LEDGF-IBD interaction inhibition dose–response curves of the compounds listed in Table 1. Data represent the means of six independent experiments with standard deviations shown as error bars. (B) Log-log correlation plot between IC50 of CCD-IBD interaction inhibition and EC50 of ARV activity for MT4 cells infected by HxB2 HIV-1. A subset of 51 Mut101 series compounds was studied (R2 = 0.77). (C) IN-LEDGF/p75 interaction inhibition dose–response curves. Data represent the means of three independent experiments with standard deviations shown as error bars. (D) Log-log correlation plot between IC50 of IN-LEDGF/p75 interaction inhibition and EC50 of ARV activity as in (B) (R2 = 0.88). (E) IN-LEDGF/p75 interaction inhibition dose–response curves for Mut101 at various LEDGF/p75 competing concentrations ranging from 7.5 nM to 480 nM. Data represent the means of two independent experiments done in quadruplicate with standard deviations shown as error bars. (F) Correlation plot between LEDGF/p75 concentration and IC50 of Mut101 IN-LEDGF interaction (R2 = 0.94).CC BY · PubMed Central
Figure 2 Structure of Mut101 bound to IN-CCD. (A) Zoomed view highlighting the hydrogen bonds between Mut101 (in green) and the IN-CCD dimer (in gold and blue). (B) Superimposition of the IN-CCD structures solved with (gold) and without (blue) Mut101. Two regions show significant differences and are highlighted by a white rectangle. (C-D) Enlargement of the two regions C and D showing the conformational changes upon ligand binding. (E-F) Solvent accessible surface coloring of IN monomers in red and gold, in absence (E) and in presence (F) of MUT101. Nitrogen atoms are in blue, oxygen in red and sulfur in yellow. Mut101 is represented in cyan. The position of K173 and E96 are shown on each monomer. The figure was made using PyMOL [73].
Figure 2 Structure of Mut101 bound to IN-CCD. (A) Zoomed view highlighting the hydrogen bonds between Mut101 (in green) and the IN-CCD dimer (in gold and blue). (B) Superimposition of the IN-CCD structures solved with (gold) and without (blue) Mut101. Two regions show significant differences and are highlighted by a white rectangle. (C-D) Enlargement of the two regions C and D showing the conformational changes upon ligand binding. (E-F) Solvent accessible surface coloring of IN monomers in red and gold, in absence (E) and in presence (F) of MUT101. Nitrogen atoms are in blue, oxygen in red and sulfur in yellow. Mut101 is represented in cyan. The position of K173 and E96 are shown on each monomer. The figure was made using PyMOL [73].CC BY · PubMed Central
Figure 3 Effect of INLAIs on IN catalytic activities. (A-B) IN strand transfer inhibition in ELISA assay: (A) The IN strand transfer inhibition of compounds listed in Table 1 is compared to inhibition with Raltegravir (RAL). Data represent the means of three independent experiments with standard deviations shown as error bars. (B) Additive effect of Mut101 and Raltegravir on IN strand transfer inhibition. Comparison of dose–response curves of Raltegravir alone and Raltegravir in the presence of 10 μM Mut101. Mean of triplicate with standard deviation. Dotted lines highlight the IC50 of Raltegravir in both conditions (difference not significant, Student’s t-test p = 0.48). (C-D) IN 3′ processing inhibition by Mut101 and BI-D assayed using standard radioactive assay: increasing concentration of Dolutegravir (DTG, from 3.3 to 100 nM), BI-D or Mut101 (from 0.01 to 100 μM) were used. The relative cleavage efficiency is reported for BI-D and Mut101 (D), and corresponds to the ratio between the product (19 bp) and the substrate (21 bp) converted to % inhibition. DTG resulted in 16% inhibition at 100 nM. (E-F) IN Strand transfer inhibition activity of Mut101 and BI-D assayed using standard radioactive assay: increasing concentration of DTG (from 0.3 to 10 nM), BI-D or Mut101 (from 0.01 to 100 μM) were used. The relative strand transfer efficiency is reported for BI-D and Mut101 (F), and corresponds to the ratio between the strand transfer products depicted on the autoradiography and the substrate (19 bp), converted to % inhibition. DTG has an IC50 of 2.7 nM.
Figure 3 Effect of INLAIs on IN catalytic activities. (A-B) IN strand transfer inhibition in ELISA assay: (A) The IN strand transfer inhibition of compounds listed in Table 1 is compared to inhibition with Raltegravir (RAL). Data represent the means of three independent experiments with standard deviations shown as error bars. (B) Additive effect of Mut101 and Raltegravir on IN strand transfer inhibition. Comparison of dose–response curves of Raltegravir alone and Raltegravir in the presence of 10 μM Mut101. Mean of triplicate with standard deviation. Dotted lines highlight the IC50 of Raltegravir in both conditions (difference not significant, Student’s t-test p = 0.48). (C-D) IN 3′ processing inhibition by Mut101 and BI-D assayed using standard radioactive assay: increasing concentration of Dolutegravir (DTG, from 3.3 to 100 nM), BI-D or Mut101 (from 0.01 to 100 μM) were used. The relative cleavage efficiency is reported for BI-D and Mut101 (D), and corresponds to the ratio between the product (19 bp) and the substrate (21 bp) converted to % inhibition. DTG resulted in 16% inhibition at 100 nM. (E-F) IN Strand transfer inhibition activity of Mut101 and BI-D assayed using standard radioactive assay: increasing concentration of DTG (from 0.3 to 10 nM), BI-D or Mut101 (from 0.01 to 100 μM) were used. The relative strand transfer efficiency is reported for BI-D and Mut101 (F), and corresponds to the ratio between the strand transfer products depicted on the autoradiography and the substrate (19 bp), converted to % inhibition. DTG has an IC50 of 2.7 nM.CC BY · PubMed Central
Figure 4 Effect of INLAIs on the oligomeric state of IN. (A-B) IN-IN HTRF interaction: (A) IN-IN interaction activation dose–response curves. Data represent the means of three independent experiments done in duplicate with standard deviations shown as error bars. (B) Correlation between AC50 of IN-IN interaction and EC50 of ARV activity on MT4 cells infected with HxB2 HIV-1 (R2 = 0.78). This study used 21 of the set of 51 compounds. AC50 = concentration required to activate IN-IN interaction by 50% of the maximum effect. (C-F) Size exclusion chromatography of IN: Binding of INLAIs BI-D or Mut101, to IN NL4-3 wt (C-D) or IN NL4-3 A128T (E-F), promotes a shift toward higher IN oligomeric state, independently of LEDGF. Blue peaks: elution of IN wt and IN A128T in the absence of compound. Red peaks: elution of IN wt and IN A128T in the presence of BI-D (C, E) or Mut101 (D, F).The elution volume and identification of each peak (numbered 1 to 7) are indicated in supplementary table S2.
Figure 4 Effect of INLAIs on the oligomeric state of IN. (A-B) IN-IN HTRF interaction: (A) IN-IN interaction activation dose–response curves. Data represent the means of three independent experiments done in duplicate with standard deviations shown as error bars. (B) Correlation between AC50 of IN-IN interaction and EC50 of ARV activity on MT4 cells infected with HxB2 HIV-1 (R2 = 0.78). This study used 21 of the set of 51 compounds. AC50 = concentration required to activate IN-IN interaction by 50% of the maximum effect. (C-F) Size exclusion chromatography of IN: Binding of INLAIs BI-D or Mut101, to IN NL4-3 wt (C-D) or IN NL4-3 A128T (E-F), promotes a shift toward higher IN oligomeric state, independently of LEDGF. Blue peaks: elution of IN wt and IN A128T in the absence of compound. Red peaks: elution of IN wt and IN A128T in the presence of BI-D (C, E) or Mut101 (D, F).The elution volume and identification of each peak (numbered 1 to 7) are indicated in supplementary table S2.CC BY · PubMed Central
Figure 5 Time of addition experiment and qPCR analysis. (A) Time-of-addition (TOA) experiment in single-round infection assay of MT4 cells infected with VSV-G-pseudotyped HIV-1 Δenv-Luc NL4-3. Each compound (Mut101, Nevirapine (NVP) or Raltegravir (RAL)) was added at the indicated times post-infection. Infection was measured by luciferase assays. Relative inhibition (%) was determined by comparison with the control. qPCR analysis of (B) the formation of proviral DNA at reverse transcription, and (C) the integration of the proviral DNA in the host cell genome after compound treatment as indicated. NI: not infected. Data represent the means of quadruplicates with standard deviations shown as error bars.
Figure 5 Time of addition experiment and qPCR analysis. (A) Time-of-addition (TOA) experiment in single-round infection assay of MT4 cells infected with VSV-G-pseudotyped HIV-1 Δenv-Luc NL4-3. Each compound (Mut101, Nevirapine (NVP) or Raltegravir (RAL)) was added at the indicated times post-infection. Infection was measured by luciferase assays. Relative inhibition (%) was determined by comparison with the control. qPCR analysis of (B) the formation of proviral DNA at reverse transcription, and (C) the integration of the proviral DNA in the host cell genome after compound treatment as indicated. NI: not infected. Data represent the means of quadruplicates with standard deviations shown as error bars.CC BY · PubMed Central
Figure 6 ARV activity in infection assays and effect on the infectivity of virions produced by HeLa-LAV cells. (A) Plot comparing the ARV activity of Mut 101 tested by MR and SR infection assays (using the same concentration scale). (B) Diagram of the experimental setup used to study infectivity of virions produced by HeLa-LAV cells that were treated with Mut101, Raltegravir, SQV, Mut063 or DMSO at the indicated concentrations. (C) Titration of p24 harvested from HeLa-LAV cells treated with the indicated compounds. (D) Infectivity of virions harvested from HeLa-LAV cells treated with the indicated compounds and tested by infection of TZM indicator cells and luciferase assay. (E) Infectivity of virions harvested from Hela-LAV cells treated with the indicated compounds and tested by infection of MT4 cells and cytopathic assay using CellTiter-Glo®.
Figure 6 ARV activity in infection assays and effect on the infectivity of virions produced by HeLa-LAV cells. (A) Plot comparing the ARV activity of Mut 101 tested by MR and SR infection assays (using the same concentration scale). (B) Diagram of the experimental setup used to study infectivity of virions produced by HeLa-LAV cells that were treated with Mut101, Raltegravir, SQV, Mut063 or DMSO at the indicated concentrations. (C) Titration of p24 harvested from HeLa-LAV cells treated with the indicated compounds. (D) Infectivity of virions harvested from HeLa-LAV cells treated with the indicated compounds and tested by infection of TZM indicator cells and luciferase assay. (E) Infectivity of virions harvested from Hela-LAV cells treated with the indicated compounds and tested by infection of MT4 cells and cytopathic assay using CellTiter-Glo®.CC BY · PubMed Central
Figure 7 Binding to IN-CCD wt, T174I mutant, treatment during production of wt and T174I mutant viruses. (A) Binding kinetics of Mut101 to IN-CCD wt. Serial dilutions of Mut101 (between 9.8 nM and 5 μM) were injected on immobilized GST-Flag-CCD wt. (B) Binding kinetics of Mut101 to IN-CCD T174I. Serial dilutions of Mut101 (between 1.3 μM and 5.0 μM) were injected on immobilized GST-Flag-CCD T174I. (C) Diagram of the experimental setup to study the infectivity of NL4-3 wt and IN T174I virions produced after transfection of 293 T cells. The indicated compounds were added during virus production for 48 h. Supernatants were tested for virus production by p24 assay, and for virus infectivity. (D) Infectivity of wt NL4-3 (blue bars) and IN T174I NL4-3 mutant (red bars) virions harvested from 293 T transfected cells after treatment with the indicated compounds and infection of MT4 cells by cytopathic assay using CellTiter-Glo®.
Figure 7 Binding to IN-CCD wt, T174I mutant, treatment during production of wt and T174I mutant viruses. (A) Binding kinetics of Mut101 to IN-CCD wt. Serial dilutions of Mut101 (between 9.8 nM and 5 μM) were injected on immobilized GST-Flag-CCD wt. (B) Binding kinetics of Mut101 to IN-CCD T174I. Serial dilutions of Mut101 (between 1.3 μM and 5.0 μM) were injected on immobilized GST-Flag-CCD T174I. (C) Diagram of the experimental setup to study the infectivity of NL4-3 wt and IN T174I virions produced after transfection of 293 T cells. The indicated compounds were added during virus production for 48 h. Supernatants were tested for virus production by p24 assay, and for virus infectivity. (D) Infectivity of wt NL4-3 (blue bars) and IN T174I NL4-3 mutant (red bars) virions harvested from 293 T transfected cells after treatment with the indicated compounds and infection of MT4 cells by cytopathic assay using CellTiter-Glo®.CC BY · PubMed Central
Figure 8 Model accounting for the discrepancy between the dual ARV activities of INLAIs at integration and post-integration. The full replication cycle of HIV is represented with steps occurring in target cells (1) separated from the steps occurring in virus-producing cells (2) by a red line. (1) Inhibitory activity at integration and competition by LEDGF in HIV-1 target cells. LEDGF is present as a chromatin-bound protein in the nucleus but is absent in the cytoplasm. After infection of target cells, IN associated with the entering virus (in blue) is imported into the nucleus as part of the pre-integration complex (PIC). Mut101 and INLAIs (yellow triangles) can bind to IN, inhibiting integration by allosteric inhibition of IN strand transfer activity and preventing IN-LEDGF complex formation. In the nucleus of target cells, LEDGF will compete with Mut101 and INLAIs for binding to IN, thus lowering their apparent affinity for IN and counteracting their antiretroviral activity at the integration stage of the replication cycle. (2) After integration, progeny virions are assembled in the cytoplasm and at the plasma membrane. INLAIs can bind to the Pol polyprotein precursor containing IN or to the matured IN, in the absence of competing LEDGF. Upon binding, these inhibitors promote conformational modification and enhancement of the IN-IN interaction resulting in IN inactivation (in red). Mut101 and INLAIs activity at the post-integration stage is stronger than their activity at integration as there is no competition with LEDGF in the cytoplasmic cellular compartment.
Figure 8 Model accounting for the discrepancy between the dual ARV activities of INLAIs at integration and post-integration. The full replication cycle of HIV is represented with steps occurring in target cells (1) separated from the steps occurring in virus-producing cells (2) by a red line. (1) Inhibitory activity at integration and competition by LEDGF in HIV-1 target cells. LEDGF is present as a chromatin-bound protein in the nucleus but is absent in the cytoplasm. After infection of target cells, IN associated with the entering virus (in blue) is imported into the nucleus as part of the pre-integration complex (PIC). Mut101 and INLAIs (yellow triangles) can bind to IN, inhibiting integration by allosteric inhibition of IN strand transfer activity and preventing IN-LEDGF complex formation. In the nucleus of target cells, LEDGF will compete with Mut101 and INLAIs for binding to IN, thus lowering their apparent affinity for IN and counteracting their antiretroviral activity at the integration stage of the replication cycle. (2) After integration, progeny virions are assembled in the cytoplasm and at the plasma membrane. INLAIs can bind to the Pol polyprotein precursor containing IN or to the matured IN, in the absence of competing LEDGF. Upon binding, these inhibitors promote conformational modification and enhancement of the IN-IN interaction resulting in IN inactivation (in red). Mut101 and INLAIs activity at the post-integration stage is stronger than their activity at integration as there is no competition with LEDGF in the cytoplasmic cellular compartment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 18

  1. Yoakim C, Deroy P, Duplessis M, Gagnon A, Goulet S, Huecke O, Lemke C, Surprenant S: Preparation of pyrazolylbenzimidazole derivatives for use as HIV replication inhibitors. Boehringer Ingelheim International GmbH, Germany. 2008, WO2008/067644 A1
  2. Tsantrizos YS, Bailey MD, Bilodeau F, Carson RJ, Coulombe R, Fader L, Halmos T, Kawai S, Landry S, Laplante S, et al: Preparation of 2-(tert-butyloxy)-2-(2-methylquinolin-3-yl)acetic acid derivatives as inhibitors of human immunodeficiency virus replication. 2009, Boehringer Ingelheim International GmbH, Germany, WO2009/062285 A1
  3. Yoakim C, Bailey MD, Bilodeau F, Carson RJ, Fader L, Kawai S, Laplante S, Simoneau B, Surprenant S, Thibeault C, Tsantrizos YS: Preparation of 2-alkoxy-2-(pyridin-3-yl)acetic acid derivatives as inhibitors of human immunodeficiency virus (HIV) replication. Boehringer Ingelheim International GmbH, Germany. 2010, WO2010/130034 A1
  4. Fenwick C, Bethell R, Bonneau P, Duan J, Faucher A, Mason S, Poupart M, Simoneau B, Tsantrizos Y, Yoakim C: Identification of BI-C, a Novel HIV-1 non-Catalytic Site Integrase Inhibitor. 2011, Boston: 18th CROI
  5. Mitchell ML, Roethle PA, Xu L, Yang H, McFadden R, Babaoglu K: Benzothiazole Compounds and Their Pharmaceutical use. 2012, US: Gilead Sciences Inc, WO2012/145728 A1
  6. Bardiot D, Chaltin P, Christ F, Debyser Z, De MM, Marchand A, Marchand D, Voet A: Preparation of Thieno[2,3-b]Pyridine Derivatives as Viral Replication Inhibitors. 2010, Katholieke Universiteit Leuven, Belg, WO2010/130842 A1
  7. Chaltin P, Debyser Z, De MM, Marchand A, Marchand D, Smets W, Voet A, Christ F: Pyrimidine Derivatives as Novel Viral Replication Inhibitors and Their Preparation and use in the Treatment of HIV Infection. 2011, Katholieke Universiteit Leuven, Belg, WO2011/015641 A1
  8. Carlens G, Chaltin P, Christ F, Debyser Z, Marchand A, Marchand D, Voet A, De MM: Novel Antiviral Compounds. 2011, Katholieke Universiteit Leuven, Belg, WO2011/076765 A1
  9. Babaoglu K, Bjornson K, Guo H, Halcomb RL, Link JO, McFadden R, Mitchell ML, Roethle P, Trenkle JD, Vivian RW, Xu L: 2-(Naphth-2-yl)Acetic Acid Derivatives as HIV Antiviral Agents and Their Preparation and use for the Treatment of AIDS. 2012, USA: Gilead Sciences, Inc, WO2012/003497 A1
  10. Babaoglu K, Bjornson K, Guo H, Halcomb RL, Link JO, Liu H, Mitchell ML, Sun J, Vivian RW, Xu L: 2-(Quinolin-6-yl)Acetic Acid Derivatives as HIV Antiviral Agents and Their Preparation and use for the Treatment of AIDS. 2012, USA: Gilead Sciences, Inc, WO2012/003498 A1
  11. Bell AS, Gardner IB, Gibson KR, Pryde DC, Wakenhut FM: Inhibitors of HIV Replication. 2012, Pfizer Ltd., GB, WO2012/066442 A1
  12. Gerritz S, Langley DR, Li G, Meanwell NA, Pendri A, Trainor GL: Inhibitors of Human Immunodeficiency Virus Replication. 2012, US: Bristol Myers Squibb Co, WO2012/033735 A1
  13. De La Rosa MA, Haidar SN, Johns BA, Velthuisen EJ: Isoquinoline Compounds and Methods for Treating HIV. 2012, US: Glaxo Smithkline LLC, WO2012/102985 A1
  14. Chasset S, Chevreuil F, Ledoussal B, Le Strat F, Benarous R: Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses. 2012, Laboratoire Biodim, FR, WO2012/137181 A1
  15. Chasset S, Chevreuil F, Ledoussal B, Le Strat F, Benarous R: Inhibitors of viral replication, their process of preparation and their therapeutical uses. Laboratoire Biodim FR. 2012, WO2012/140243 A1
  16. Hattori K, Kurihara N, Iwaki T, Inoue T, Akiyama T, Hasegawa Y: HIV Replication Inhibitor. 2013, Shionogi & Co., JP, WO2013/002357 A1
  17. Yant S, Tsai L, O’Sullivan C, Cihlar T, Balakrishnan M: Conference on Retroviruses and Opportunistic Infections. Non-Catalytic Site Integrase Inhibitors Target the Integrase Domain During Virus Production and Induce a Reverse Transcription Block. 2013, Gilead Sciences: Atlanta, GA, USA
  18. Fenwick C, Tremblay S, Wardrop E, Bethell R, Coulombe R, Elston R, Faucher A-M, Mason S, Simoneau B, Tsantrizos Y, Yoakim C: Resistance Studies with HIV-1 non-Catalytic Site Integrase Inhibitors. 2011, Cabo, Mexico: In International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies

Cited by

See all 135

Metadata

Authors
Le Rouzic, E., Bonnard, D., Chasset, S., Bruneau, J.-M., Chevreuil, F., Le Strat, F., Nguyen, J., Beauvoir, R., Amadori, C., Brias, J., Vomscheid, S., Eiler, S., Lévy, N., Delelis, O., Deprez, E., Saïb, A., Zamborlini, A., Emiliani, S., Ruff, M., Ledoussal, B., Moreau, F., & Benarous, R.
Affiliations
  • Mutabilis (France) (FR)
  • Centre National de la Recherche Scientifique (FR)
  • École Normale Supérieure Paris-Saclay (FR)
  • Conservatoire National des Arts et Métiers (FR)
Venue
Retrovirology
Published
2013-11-21
Volume
10
Issue
1
Pages
144-144
ISSN
1742-4690 (ISSN-L)
OpenAlex
W2150698261
Cited by
127
References
65
Citations by year
2026: 2 · 2025: 7 · 2024: 8 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 12 · 2019: 13 · 2018: 12 · 2017: 10 · 2016: 16 · 2015: 8 · 2014: 11
FWCI
8.47
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Retrovirology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by)
  • univOAK (4 institutions : Université de Strasbourg, Université de Haute Alsace, INSA Strasbourg, Bibliothèque Nationale et Universitaire de Strasbourg) (submittedVersion, cc-by)
Funders
  • Sidaction
  • European Commission (305137)
  • Agence Nationale de la Recherche (ANR-10-INSB-05-01., 10-INSB-05-01, ANR- 10-INSB-05, ANR-10, ANR-10-INBS-0005)
  • Institut National de la Santé et de la Recherche Médicale
  • Paul Scherrer Institut
  • Centre National de la Recherche Scientifique
  • Shionogi
  • French Infrastructure for Integrated Structural Biology (FRISBI, ANR-10-INSB-05-01, ANR-10- INSB-05, ANR-10-INSB-0501, INSB-05)
  • National Institutes of Health
  • CHIST-ERA
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
HIV-1 integrase, LEDGF/p75, allosteric inhibitors, viral infectivity, integrase inhibitor resistance, antiretroviral activity, crystal structure
MeSH terms
Cell Line, Humans, Protein Binding, Protein Conformation, Virus Replication, HIV-1, Virus Integration, Crystallography, X-Ray, HIV Integrase, HIV Integrase Inhibitors, Intercellular Signaling Peptides and Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. https://app.cochat.ai/papers/10.1186/1742-4690-10-144
The paper
Le Rouzic, E., Bonnard, D., Chasset, S., Bruneau, J.-M., Chevreuil, F., Le Strat, F., Nguyen, J., Beauvoir, R., Amadori, C., Brias, J., Vomscheid, S., Eiler, S., Lévy, N., Delelis, O., Deprez, E., Saïb, A., Zamborlini, A., Emiliani, S., Ruff, M., . . . Benarous, R. (2013). Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. Retrovirology. https://doi.org/10.1186/1742-4690-10-144

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.